ASCO 2020: Roche Highlights TIGIT As Tecentriq Bags Another Approval
FDA Okays Practice-Changing Treatment For Liver Cancer
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.
You may also be interested in...
Putting aside the coronavirus pandemic for a while, and turning to industry’s more bread and butter R&D activities, Scrip takes a look at the industry’s biggest clinical trial hits and misses of the year.
A number of anti-TIGIT drugs are jockeying for position to provide benefit as monotherapies and in combinations for non-small cell lung cancer and Merck's offering is looking to challenge Roche's tiragolumab for the lead.
PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival.